Using L-Arginine to treat children with Sickle Cell Disease and heart issues
Official title: Clinical Study to Evaluate the Possible Efficacy and Safety of L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity
Run by Tanta University · NCT05470998 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing if L-Arginine can help children with Sickle Cell Disease and heart issues feel better and improve their heart function.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 5 Years to 18 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta, Other (Non U.s.)) |
| Trial ID | NCT05470998 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children aged 5-18 years diagnosed with Sickle Cell Disease and increased Tricuspid Regurgitant Jet Velocity.
✕Probably not a fit
Patients with other chronic hemolytic anemias, documented pulmonary hypertension from causes other than Sickle Cell Disease, or those with allergies to L-Arginine may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the efficacy and safety of L-Arginine in children aged 5 to 18 years who have Sickle Cell Disease and exhibit increased Tricuspid Regurgitant Jet Velocity. The intervention aims to assess whether L-Arginine can improve heart function and overall health in these patients. The study is interventional and is classified as a Phase 3 trial, indicating it is designed to confirm effectiveness and monitor side effects in a larger population.
Why it matters
Potential benefit: If successful, this treatment could improve heart function and quality of life for children suffering from Sickle Cell Disease.
How similar studies have gone: While this specific approach may be novel, similar studies exploring treatments for Sickle Cell Disease have shown varying degrees of success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * children having Sickle Cell Disease with increased Tricuspid Regurgitant Jet Velocity * age 5-18 years Exclusion Criteria: * Another chronic hemolytic anemia. * Patients with documented causes of pulmonary hypertension other than SCD. * Allergy to L-arginine. * Patients with Asthma. * Hepatic dysfunction: serum Alanine Aminotransferase (ALT) \> 3X upper value. * Renal dysfunction: Creatinine level greater than or equal to 1.2 mg/dl.
Where it's running
-
Tanta university
Tanta, Other (Non U.s.), Egypt Recruiting
Study contacts
- Principal investigator: dalia A gomaa — Tanta University
- Study coordinator: dalia A gomaa
- Email: dalia_gomaa@pharm.tanta.edu.eg
- Phone: 01063410525
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cerebrovascular Reactivity Testing with HD-DOT in Sickle Cell Patients
This study tests whether high-density diffuse optical tomography can measure brain blood flow and oxygen use in people with sickle cell disease, to see how these signals relate to stroke risk.
-
Adapting and testing PEN-Plus in Zambian primary care
Aiming to see if the PEN-Plus package can be adapted and used in two Zambian hospitals to better manage chronic diseases like heart disease, diabetes, hypertension, and sickle cell in primary care.
-
Newborn Sickle Cell Screening in Mozambique
We’re testing a three-part plan to help babies in Mozambique get diagnosed early for sickle cell disease and start care quickly.
-
Optimizing Hydroxyurea in Children with Sickle Cell in Africa
This study tests whether raising hydroxyurea to a maximum tolerated dose is safe and beneficial for Ugandan children with sickle cell anemia already taking a fixed daily dose.
-
Hematopoietic stem cell editing to treat sickle cell disease
This study tests whether a patient’s own blood stem cells can be edited to remove the sickle cell triggering gene and then returned to the patient.
-
Virtual reality options to help with VOC pain in adults with SCD
This study tests whether headset-based virtual reality can help reduce pain for adults with sickle cell disease during vaso-occlusive crises treated in an infusion center.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.